Eli Lilly agrees to acquire Orna Therapeutics for up to $2.4B
Indianapolis-based Eli Lilly and Company (NYSE:LLY) announced on February 9, 2026, that it has agreed to acquire Orna Therapeutics, a biotechnology company pioneering circular RNA and novel lipid nanoparticle (LNP) delivery technologies for in vivo cell therapies.





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













